This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Long-term lanreotide: median PFS 32.8 months from OLE entry for continuous lanreotide patients. Placebo-to-lanreotide crossover patients had 14.0 months PFS.
Why it matters
Confirms sustained antiproliferative benefit of lanreotide beyond 96 weeks, supporting long-term use.
The numbers in context
Median PFS 32.8 months (continuous); 14.0 months (crossover)
How the study worked
Open-label extension of CLARINET phase 3 trial. All patients received lanreotide 120mg q28d.
Who was studied
CLARINET completers with metastatic G1/G2 enteropancreatic NETs
What this study cannot tell us
Open-label, no blinded comparison. Selection bias in extension enrollment.
Read the original research
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Endocrine, 71(2), 502-513
Citation
Caplin, Martyn E; Pavel, Marianne; Phan, Alexandria T; Cwikla, Jaroslaw B; Sedlackova, Eva; Cadiot, Guillaume; Wolin, Edward M; Capdevila, Jaume; Wall, Lucy; Rindi, Guido; Langley, Alison; Martinez, Santiago; Ruszniewski, Philippe. (2021). Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.. Endocrine, 71(2), 502-513. https://doi.org/10.1007/s12020-020-02475-2